|
(Health-NewsWire.Net, July 30, 2015 ) Cancer Pain - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Cancer Pain - Pipeline Review, H1 2015” which provides an overview of the Cancer Pain pipeline.
This report gives extensive data on the remedial improvement for Cancer Pain, complete with similar examination at different stages, therapeutics evaluation by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent redesigns, and included news and press discharges. It likewise audits key players included in the restorative advancement for Cancer Pain and extraordinary elements on late-stage and suspended undertakings.
The report improves choice making abilities and help to make viable counter methods to increase upper hand. It fortifies R&D pipelines by distinguishing new targets and MOAs to create first-in-class and best-in-class items.
Complete report on H1, 2015 Pipeline Review of “Cancer Pain” addition with 54 market data tables and 15 figures, spread across 137 pages is http://www.rnrmarketresearch.com/cancer-pain-pipeline-review-h1-2015-market-report.html .
This report highlights investigational meds from across over globe covering more than 20 treatment ranges and around 3,000 proofs. The report is gathered using data and information sourced from our selective databases, Company/University locales, SEC filings, money related master presentations and included press releases from association/school destinations and industry-specific untouchable sources, set up together by our gathering. Prescription profiles/records highlighted in the report encounters irregular updating taking after a stringent plan of systems that ensures that each one of the profiles are upgraded with the latest course of action of information. Additionally, techniques including live news & courses of action taking after, project based prepared box and clinical trials registries taking after assurance that the most recent changes are discovered on a progressing reason.
Companies Discussed/Mentioned in this Research:
Amgen Inc., Amorsa Therapeutics Inc., AngioChem Inc., Aphios Corporation, AstraZeneca Plc, BCN Peptides, S.A., Benitec Biopharma Limited, BioDelivery Sciences International, Inc., ChironWells GmbH, Daiichi Sankyo Company, Limited, Grunenthal GmbH, GW Pharmaceuticals Plc, Immupharma Plc, IntelGenx Corp., Kolon Life Science, Inc., Nektar Therapeutics, Neurocentrx Pharma Ltd., Nippon Kayaku Co., Ltd., Northern Light Pharmaceuticals AB, Orion Oyj, Pain Therapeutics, Inc., Pfizer Inc., Pharmaleads, Recordati S.p.A., Sorrento Therapeutics, Inc., Virobay Inc., Winston Pharmaceuticals, Inc. and Zynerba Pharmaceuticals, Inc.
Drugs Profile Discussed in this Research :
AMS-410 ER12, ANG-2002, BBI-11008, calpastatin, cebranopadol, crotalphine, DD-04107, dexmedetomidine hydrochloride, dronabinol, Drug for Cancer Neuropathic Pain, fentanyl, fentanyl citrate, fentanyl citrate, fulranumab, HS-198, hydromorphone hydrochloride, INT-0028, IPP-102199, ketamine hydrochloride ER, KLS-2010, methadone hydrochloride, nabiximols, Nervarna, NKTR-192, Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia, PGN-202, PL-265, Q-201, QX-314, resiniferatoxin, saracatinib difumarate, Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy, Small Molecule to Antagonize Chemokine Receptor for Cancer Pain, tanezumab, VBY-825, zucapsaicin and ZYN-001
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=397268 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Cancer Pain
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Cancer Pain
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Pain Management Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
